Clinical Trial

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This open-label, multicenter Ib/II phase clinical trial investigates the safety, tolerability, and preliminary efficacy of tislezumab (anti-PD-1 monoclonal antibody), golidocitinib (JAK1/STAT3 signaling pathway inhibitor), and selinexor (selective inhibitor of nuclear export, XPO1 antagonist) in patients with relapsed/refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) progressing after ≥1 line of L-asparaginase-containing chemotherapy or chemoradiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-02.
Status change: Not Yet Recruiting → Recruiting 2025-05-26
Trial Details
NCT Number NCT06966154
Lead Sponsor Fudan University
Conditions Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL
Enrollment 68 participants
Start Date 2025-05-26
Primary Completion 2027-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-30